Buchanan laboratory: Oncogenomics (colorectal cancer)
Research Program Leader : Dr Daniel BuchananThe Oncogenomics Group research includes the identification and investigation of clinically and biologically relevant subtypes of colorectal cancer (CRC), including both familial and non-familial CRC, that can be identified through genetic, epigenetic, somatic and histopathological characterisation of CRC tumours and their pre-malignant lesions (polyps).
Coin Laboratory: Cancer Bioinformatics
Interrogating genome and transcriptome data to identify biomarkers and create new diagnostic tools in cancer
- Characterisation of complex structural variation in bacterial and human genomes
- Genomic tools for diagnosis of the presence of a solid tumour and for prediction of tumour subtype and likely treatment response from circulating tumour DNA
- Genomic tools for rapid diagnosis of bacterial infection using host and bacterial biomarkers
Genomics Platform Group
Research Program Leader : Associate Professor Oliver Hofmann
Working on improved scalability and reliability of sequencing workflows, better detection of changes in cancer genomes, and aims to make tumour data, especially molecular data, from medical institutions and other organisations, accessible for research use in real time.
Hollande laboratory: Tumour Heterogeneity in Metastatic Cancer
Research Program Leader : Associate Professor Fred Hollande
Understanding the mechanisms that underlie the genetic and non-genetic heterogeneity within individual tumours, and characterising signalling pathways that specify the differential behaviour of cell subpopulations that drive metastatic progression and treatment response.
Rare Disease Oncogenomics
Research Program Leader : Dr Richard Tothill
The Rare Disease Oncogenomics (RADIO) laboratory is dedicated to translational research of rare and less common cancers. Our research encompasses neuroendocrine tumours (NET), including tumours of sympathetic tissues (pheochromocytoma and parganglioma) and skin (Merkel cell carcinoma), as well as cancers of unknown primary (CUP).